Misoprostol
- Generic Name
- Misoprostol
- Brand Names
- Arthrotec, Cytotec, Mifegymiso
- Drug Type
- Small Molecule
- Chemical Formula
- C22H38O5
- CAS Number
- 59122-46-2
- Unique Ingredient Identifier
- 0E43V0BB57
- Background
Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions. The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the strength and frequency of contractions and decrease cervical tone.
Misoprostol was granted FDA approval on 27 December 1988.
- Indication
Misoprostol is indicated as a tablet to reduce the risk of NSAID induced gastric ulcers but not duodenal ulcers in high risk patients. Misoprostol is also formulated in combination with diclofenac to treat symptoms of osteoarthritis or rheumatoid arthritis in patients with a high risk of developing gastric ulcers. Misoprostol is used off label for the management of miscarriages, prevention of post partum hemorrhage, and is also used alone or in combination with mifepristone in other countries for first trimester abortions.
- Associated Conditions
- Gastric Ulcer, Incomplete Abortion, Missed Abortion, Postpartum Haemorrhage (PPH)
- Associated Therapies
- Induction of cervix ripening therapy, Medically induced abortion
Misoprostol for NASH
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- Ziauddin University
- Target Recruit Count
- 50
- Registration Number
- NCT05804305
- Locations
- 🇵🇰
Dr. Ziauddin Hospital Clifton, Karachi, Sindh, Pakistan
Preoperative Vaginal Dinoprostone Versus Misoprostone in Abdominal Myomectomy
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2023-03-09
- Lead Sponsor
- Beni-Suef University
- Target Recruit Count
- 90
- Registration Number
- NCT05761418
- Locations
- 🇪🇬
Beni-suef university, Banī Suwayf, Egypt
Oral and Vaginal Misoprostol for Induction of Labor in Nulliparous Pregnant Women
- Conditions
- LaborPregnancyMisoprostolNulliparous
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 80
- Registration Number
- NCT05696574
Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction (PROBIN)
- Conditions
- Fetal Growth Restriction
- Interventions
- Device: Trans-cervical balloon
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- University Hospital, Bordeaux
- Target Recruit Count
- 774
- Registration Number
- NCT05674487
- Locations
- 🇫🇷
CHU Bordeaux, Bordeaux, France
Balloon + Oxytocin Versus Oral Misoprostol to Induce Labor in Case of PROM (RUBAPRO2)
- Conditions
- Cervical RipeningPremature Rupture of Fetal MembranesInduction of LaborNulliparous
- Interventions
- Device: Balloon for cervical ripening (Teleflex French Dufour catheter CH20 reference 174000)
- First Posted Date
- 2022-10-06
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- University Hospital, Clermont-Ferrand
- Target Recruit Count
- 520
- Registration Number
- NCT05568745
- Locations
- 🇫🇷
CHU de Saint Etienne, Saint-Étienne, France
🇫🇷CHU de Toulouse, Toulouse, France
🇫🇷CHU de Clermont-Ferrand, Clermont-Ferrand, France
Sublingual Misoprostol in Reduction of Caesarean Blood Loss
- Conditions
- Post Partum Hemorrhage
- Interventions
- First Posted Date
- 2022-09-08
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- OZORI EBIOGBO STANLEY
- Target Recruit Count
- 152
- Registration Number
- NCT05532215
- Locations
- 🇳🇬
Federal Medical Centre Yenagoa, Yenagoa, Bayelsa, Nigeria
MISOBEST - Orally Misoprostol Solution (Cytotec®) Versus Orally Misoprostol as a Tablet (Angusta®) for Induction of Labor
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Karolinska Institutet
- Target Recruit Count
- 884
- Registration Number
- NCT05424445
- Locations
- 🇸🇪
Södersjukhuset, Stockholm, Sweden
Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 9
- Registration Number
- NCT05342974
- Locations
- 🇺🇸
Planned Parenthood Association of Utah, Salt Lake City, Utah, United States
Blood Loss During Cesarean Delivery in Placenta Previa Patients
- Conditions
- Placenta Previa
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2023-01-06
- Lead Sponsor
- Cairo University
- Target Recruit Count
- 81
- Registration Number
- NCT05340205
- Locations
- 🇪🇬
Kasralainy Cairo University, Giza, Egypt
Simultaneous Mifepristone and Misoprostol Versus Misoprostol Alone for Induction of Labor of Nonviable Second Trimester Pregnancy: a Pilot Randomized Controlled Trial
- Conditions
- Fetal DeathFetal Demise From MiscarriageAbortion, Second TrimesterPregnancy ComplicationsPPROMRupture, SpontaneousFetal DemiseFetal Death Before 22 Weeks With Retention of Dead FetusPregnancy Loss
- Interventions
- First Posted Date
- 2022-04-11
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 30
- Registration Number
- NCT05322252
- Locations
- 🇺🇸
Barnes-Jewish Hospital, Saint Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.